TY - JOUR
T1 - Follicular extension of atypical keratinocytes predicts the resistance of actinic keratosis to topical imiquimod treatment
T2 - A single-center retrospective analysis
AU - Tanaka, Ryo
AU - Tanese, Keiji
AU - Zhu, Yingyao
AU - Fujio, Yumi
AU - Konohana, Izumi
AU - Kurihara, Yuichi
N1 - Funding Information:
We thank Sanae Nirayama, Choko Maekawa, and Yukie Furuse for their assistance in the clinical work and support in data analysis.
Publisher Copyright:
© 2021 Japanese Dermatological Association
PY - 2021/8
Y1 - 2021/8
N2 - Topical imiquimod therapy has been widely used for actinic keratosis (AK). However, some cases are refractory to treatment. Therefore, an indicator that can predict its efficacy is desired. Herein, we retrospectively analyzed 52 AK lesions treated with imiquimod to investigate the characteristics of refractory lesions. Imiquimod was applied in a cycle of three times weekly for 4 weeks, followed by a 4-week break. This treatment cycle was repeated up to three times and treatment responses were evaluated. As a result, a complete response (CR) was observed in 78.8% (41/52) of lesions. Next, treatment response of lesions was correlated with clinicopathological characteristics including clinical morphology and thickness, pathological morphology and thickness, and presence of follicular extension (FE). Of these, lesions with FE were significantly less responsive to imiquimod treatment; while 92.6% of AK lesions without FE achieved a CR, only 64.0% of AK lesions with FE achieved a CR (p = 0.029). Logistic regression analysis revealed that FE was the sole significant predictor of its efficacy (p = 0.019). These results suggest that preliminary histological evaluation of FE may be useful to predict the efficacy of imiquimod for AK.
AB - Topical imiquimod therapy has been widely used for actinic keratosis (AK). However, some cases are refractory to treatment. Therefore, an indicator that can predict its efficacy is desired. Herein, we retrospectively analyzed 52 AK lesions treated with imiquimod to investigate the characteristics of refractory lesions. Imiquimod was applied in a cycle of three times weekly for 4 weeks, followed by a 4-week break. This treatment cycle was repeated up to three times and treatment responses were evaluated. As a result, a complete response (CR) was observed in 78.8% (41/52) of lesions. Next, treatment response of lesions was correlated with clinicopathological characteristics including clinical morphology and thickness, pathological morphology and thickness, and presence of follicular extension (FE). Of these, lesions with FE were significantly less responsive to imiquimod treatment; while 92.6% of AK lesions without FE achieved a CR, only 64.0% of AK lesions with FE achieved a CR (p = 0.029). Logistic regression analysis revealed that FE was the sole significant predictor of its efficacy (p = 0.019). These results suggest that preliminary histological evaluation of FE may be useful to predict the efficacy of imiquimod for AK.
KW - actinic keratosis
KW - clinical classification
KW - follicular extension
KW - imiquimod
KW - pathological classification
UR - http://www.scopus.com/inward/record.url?scp=85105069853&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105069853&partnerID=8YFLogxK
U2 - 10.1111/1346-8138.15914
DO - 10.1111/1346-8138.15914
M3 - Article
C2 - 33896047
AN - SCOPUS:85105069853
SN - 0385-2407
VL - 48
SP - 1262
EP - 1267
JO - Journal of Dermatology
JF - Journal of Dermatology
IS - 8
ER -